Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Moran (Oxford, United Kingdom), S. Ramakrishnan (Oxford, United Kingdom), C. Borg (Oxford, United Kingdom), C. Connolly (Oxford, United Kingdom), S. Couillard (Oxford, United Kingdom), C. Mwasuku (Oxford, United Kingdom), I. Pavord (Oxford, United Kingdom), T. Hinks (Oxford, United Kingdom), L. Lehtim?ki (Tampere, Finland). Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma. 2252

Member's Comments

No comment yet.

Related content which might interest you: Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma Source: International Congress 2017 – Asthma management Year: 2017 Treatment of moderate-severe asthma with omalizumab is associated with a decrease in peripheral blood eosinophils Source: Eur Respir J 2007; 30: Suppl. 51, 353s Year: 2007 Association between blood eosinophil count and exacerbation risk in patients with asthma receiving medium- or high-dosage inhaled corticosteroids Source: International Congress 2017 – Biomarker-based asthma control Year: 2017 Increase in systemic IL-5 is associated with mepolizumab treatment failure in patients with severe asthma Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Anti-inflammatory effects of high-dose inhaled fluticasone versus oral prednisone in asthma exacerbations Source: Eur Respir J 2007; 30: 1143-1149 Year: 2007 One year monitoring of children with bronchial asthma and other allergic diseases treated with inhaled corticosteroids vs cromoglycates with serum ECP (S-ECP), FEV1, total IgE and blood eosinophil count - the influence of different therapy Source: Eur Respir J 2002; 20: Suppl. 38, 432s Year: 2002 Decreasing dose protocol for omalizumab treatment in oral corticosteroid allergic asthma patients Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011 Regulatory T cells and L-selectin in severe asthmatic patients treated with mepolizumab. Source: Virtual Congress 2020 – Personalised treatment of obstructive diseases Year: 2020 Evolution of patients with severe asthma treated with mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 High sputum eosinophils are associated with better response to inhaled corticosteroids in asthmatic patients Source: Eur Respir J 2002; 20: Suppl. 38, 113s Year: 2002 The effect of anti-IL-5 therapy on sputum cells and cytokines in asthmatics Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics Source: Eur Respir J 2001; 18: 254-261 Year: 2001 Long-term safety and tolerability of omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Ciclesonide 80 μg once daily reduces early and late asthmatic reaction, sputum eosinophils and serum ECP in asthma patients challenged with allergens Source: Eur Respir J 2005; 26: Suppl. 49, 254s Year: 2005 Assessment and evaluation of symptomatic steroid-naive asthmatics without sputum eosinophilia and their response to inhaled corticosteroids Source: Eur Respir J 2002; 20: 1364-1369 Year: 2002 Absence of sputum eosinophils in subjects with symptomatic asthma on inhaled budesonide Source: Eur Respir J 2002; 20: Suppl. 38, 274s Year: 2002 Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study Source: Eur Respir J, 51 (5) 1702523; 10.1183/13993003.02523-2017 Year: 2018 Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma Source: Eur Respir J 2005; 25: 41-46 Year: 2005 Long-term asthma control with omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 47s Year: 2005